NCT06850402

Brief Summary

All patients will be enrolled in Mozambique and Brazil. They will provide informed consent to use their cervical biopsy and/or LEEP specimens for imaging with DeepDOF prior to sending for standard of care processing and interpretation.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for not_applicable

Timeline
27mo left

Started Jun 2026

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 17, 2025

Completed
10 days until next milestone

First Posted

Study publicly available on registry

February 27, 2025

Completed
1.3 years until next milestone

Study Start

First participant enrolled

June 1, 2026

Expected
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2027

1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2028

Last Updated

March 9, 2026

Status Verified

March 1, 2026

Enrollment Period

1.3 years

First QC Date

February 17, 2025

Last Update Submit

March 5, 2026

Conditions

Keywords

HPV DNA Testing

Outcome Measures

Primary Outcomes (1)

  • Primary Out Measures

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

    through study completion, an average of 1 year

Study Arms (1)

DeepDOF Images

EXPERIMENTAL

Participants will be approached by a trained research assistant. After informed consent is obtained, each participant will collect two cervical swabs (self-collected and/or provider-collected) as an optional procedure and stored for future research. VIA and/or colposcopy will be performed per standard of care. Cervical biopsy(ies) and/or LEEP will be performed per standard of care. The specimens will be imaged immediately using DeeDOF at the point of care and then submitted for standard histopathologic analysis as shown in Figure 1.

Device: DeepDOF Images

Interventions

Women referred for consultation for cervical biopsy(ies) and/or LEEP will be recruited into the experimental group of the study.

DeepDOF Images

Eligibility Criteria

Age25 Years - 49 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsFemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Women aged 25 - 49 years
  • women undergoing cervical biopsy and/or LEEP
  • Women who are not pregnant and with a negative pregnancy test (within 3 days of enrollment)
  • Willing and capable of providing informed consent

You may not qualify if:

  • Women under 25 or over 49 years of age
  • Women not undergoing cervical biopsy or LEEP
  • Women who are pregnant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The University of Texas M. D. Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Related Links

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Officials

  • Kathleen M Schmeler, MD

    M.D. Anderson Cancer Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Kathleen M Schmeler, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 17, 2025

First Posted

February 27, 2025

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

September 1, 2028

Last Updated

March 9, 2026

Record last verified: 2026-03

Locations